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Abstract: HSP47 (heat shock protein 47) is a collagen-specific molecular chaperone that is essential 
for procollagen folding and function. Previous studies have shown that HSP47 binding requires a 
critical Arg residue at the Y position of the (Gly-Xaa-Yaa) repeats of collagen; however, the exact 
binding sites of HSP47 on native collagens are not fully defined. To address this, we mapped the 
HSP47 binding sites on collagens through an ELISA binding assay using collagen toolkits, synthetic 
collagen peptides covering the entire amino acid sequences of collagen types II and III assembled 
in triple-helical conformation. Our results showed that HSP47 binds to only a few of the GXR motifs 
in collagen, with most of the HSP47 binding sites identified located near the N-terminal part of the 
triple-helical region. Molecular modelling and binding energy calculation indicated that residues 
flanking the key Arg in the collagen sequence also play an important role in defining the high-
affinity HSP47 binding site of collagen. Based on this binding mode of HSP47 to collagen, virtual 
screening targeting both the Arg binding site and its neighboring area on the HSP47 surface, and a 
subsequent bioassay, we identified two novel compounds with blocking activity towards HSP47 
binding of collagen. Overall, our study revealed the native HSP47 binding sites on collagen and 
provided novel information for the design of small-molecule inhibitors of HSP47. 
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1. Introduction 
Collagen is the most abundant protein in mammals and is critical for forming 
specialized extracellular networks that bind cells together. The folding, processing, and 
assembly of collagen is tightly regulated in eukaryotic cells. Procollagen, the precursor 
molecule of collagen, undergoes extensive posttranslational processing to assemble into 
a triple-helical collagen, following which mature collagen is then secreted [1,2]. During 
these processes, several molecular chaperones and enzymes such as prolyl hydroxylase 
and heat shock protein 47 (HSP47) are involved.  
HSP47 is a member of the serpin family, but it lacks serine protease inhibitory activity 
[3]. It normally resides in the endoplasmic reticulum (ER) and functions as a collagen-
specific molecular chaperone [4–6]. HSP47 associates transiently with procollagen in the 
ER, thereby preventing premature interactions between nascent procollagen molecules, 
and dissociates when procollagen transfers to cis-Golgi [7]. HSP47 knockout mice are 
Citation: Cai, H.; Sasikumar, P.; 
Little, G.; Bihan, D.; Hamaia, S.W.; 
Zhou, A.; Gibbins, J.M.; Farndale, 
R.W. Identification of HSP47 
Binding Site on Native Collagen and 
Its Implications on The 
Development of HSP47 Inhibitors. 
Biomolecules 2021, 11, 983. 
https://doi.org/10.3390/ 
biom11070983 
Academic Editor: Maria Stefania 
Sinicropi  
Received: 9 June 2021 
Accepted: 30 June 2021 
Published: 3 July 2021 
Publisher’s Note: MDPI stays 
neutral with regard to jurisdictional 
claims in published maps and 
institutional affiliations. 
 
Copyright: © 2021 by the authors. 
Licensee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and 
conditions of the Creative Commons 
Attribution (CC BY) license 
(http://creativecommons.org/licenses
/by/4.0/). 
Biomolecules 2021, 11, 983 2 of 12 
 
 
embryonic-lethal 11.5 days post-coitus [8], and aberrant formation of triple-helical 
collagen I molecules as well as defects in collagen production and basement membrane 
formation have been detected in these embryos. This indicates that HSP47 is essential for 
the correct folding of procollagen. 
Overexpression of HSP47 is associated with abnormal deposition of collagens in the 
extracellular matrix (ECM), with the onset of various fibroses, including liver cirrhosis, 
lung, bone marrow, and idiopathic pulmonary fibroses [9,10]. No specific treatment is 
currently available for these fibrotic diseases, which often lead to organ or tissue 
failure [11]. Nevertheless, the progression of fibrosis could be markedly reduced when 
HSP47 expression is suppressed using siRNA-mediated knockdown [12,13]. Altered 
HSP47 expression levels are also found to correlate with the development of several types 
of cancer, such as cervical, breast, pancreatic, and gastric cancers [13,14]. Silencing HSP47 
significantly inhibits cell invasion in breast cancer cells and inhibited tumor growth in a 
xenograft mammary tumor model [4,15]. Our recent studies showed that HSP47 is present 
on the platelet surface and is involved in the recognition and response to collagen [16]. It 
is plausible that aberrant expression of HSP47 may contribute to the onset of various 
cardiovascular diseases. As HSP47 is the only collagen-specific molecular chaperone, 
targeting its binding interactions with collagen could be an effective therapeutic approach 
in managing these HSP47-overexpression-related diseases. Several types of small 
molecules have been developed as HSP47 inhibitors [17–20]. Recently, one of these 
compounds (COM IV) was reported to effectively prevent collagen synthesis, cell 
viability, and migration of lung fibroblasts [21]. 
There have been extensive biochemical and structural studies on the binding 
interactions between HSP47 and collagen using short synthetic collagen–mimetic peptides 
[7,22,23]. These showed that HSP47 binds to triple-helical peptides containing a key Arg 
residue at the Y position of collagenous repeats (Gly-Xaa-Yaa). These results were 
confirmed by X-ray crystal structures of collagen model peptides (designated CMPs) 
complexed with canine HSP47 [24]; however, the exact binding sites of HSP47 on native 
collagens are not fully defined. For example, there are more than 40 arginine residues at 
similar Y positions in collagen II or III, and it is unclear if HSP47 could bind them all. To 
clarify this, here we have mapped the HSP47 binding sites using collagen toolkits and 
identified HSP47 binding sites on collagens II and III. This provides novel information on 
the binding mode of HSP47 on collagen and sheds light on the development of novel 
HSP47 inhibitors.  
2. Materials and Methods  
2.1. Expression and Purification of HSP47  
Genes encoding human HSP47 (amino acids 19-418) were cloned in pET-28a. Proteins 
were expressed with C-terminal His-tag in E. coli BL21 (DE3). Cells were cultured at 37 °C 
in LB and induced with 0.5 mM IPTG (isopropyl-β-D-thiogalactoside) until A600 reached 
1. After a further 16 h incubation at 25 °C, cells were collected by centrifugation, then 
resuspended in lysis buffer (20 mM Tris-HCl pH 7.4, 0.5 M NaCl) and lysed by high 
pressure. His-tagged HSP47 in the supernatant was isolated by nickel-affinity 
chromatography (GE Healthcare). The column was washed with wash buffer (20 mM Tris-
HCl pH 7.4, 0.5 M NaCl, 20 mM imidazole) and step-eluted with elution buffer (20 mM 
Tris-HCl pH 7.4, 0.5 M NaCl, 300 mM imidazole). The peak fractions were pooled and 
dialyzed against final buffer (20 mM Tris-HCl pH 7.4, 0.5 M NaCl) and purity determined 
by SDS–PAGE. 
2.2. Binding of HSP47 to Toolkit Peptides 
The peptides of the collagen II and III toolkits were synthesized on TentaGel R Ram 
resin using a CEM Liberty microwave-assisted peptide synthesizer as described 
previously [22,25]. Briefly, the host–guest strategy was applied, whereby the guest 
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sequence, which is the native collagen sequence of interest, is placed between (GPP)5 
hosts, which are the flanking sequences that impart triple-helical conformation on the 
whole peptide; thus, toolkits II and III encompassed the entire collagen domains of human 
collagens II and III, respectively. Binding of HSP47 to the toolkit peptides was determined 
colorimetrically by solid-phase binding assay (SPBA). Peptides were coated at 10 µg/mL 
overnight at 4 °C on Immulon 2HB 96-well plates (Thermo Scientific, Loughborough, UK) 
and blocked for 1 h with 175 µl of binding buffer (TBS containing 5% BSA) before the 
addition of 100 µl of binding buffer containing 1 µg/mL recombinant HSP47 for 1 h at 
room temperature. Wells were washed five times with 200 µl of binding buffer (TBS 
containing 0.1% BSA w/v). Then, binding buffer was added containing HRP (horseradish 
peroxidase)-conjugated anti-His antibody at 1:1000 dilution, followed by incubation for 1 
h at room temperature. After washing, color was developed using a Pierce TMB (3,3′,5,5′-
tetramethylbenzidine) Substrate Kit (Thermo Scientific, Loughborough, UK) according to 
the manufacturer’s instructions. 
2.3. Virtual Screening of Small Inhibitors Targeting Human the HSP47/Collagen Binding 
Interface 
As the sequence similarity between canine and human HSP47 is 99%, and residues 
involved in collagen binding are all conserved, the human HSP47 structure was modelled 
by SWISS-MODEL [26] using the canine HSP47 crystal structure (PDB ID: 3ZHA) [24] as 
the template. The triple-helical structure of HSP47–integrin peptide I was built using 
software FoldX [27] based on the structure of the HSP47–CMP complex (PDB ID: 3ZHA) 
and our previously reported integrin peptide I structure (PDB ID: 1Q7D).  
To select potential HSP47 inhibitors, the SPECS database (http://www.specs.net) 
containing structural information for approximately 100,000 chemicals (logP≤ 5.5 and 
logS≥ –5.5) was adopted for virtual screening using software Glide6.9 
(www.schrödinger.com). The docking model for HSP47 was prepared using the Protein 
Preparation and Grid Preparation tools in the Schrödinger Maestro interface. In the grid 
preparation process, the default settings were adopted for the cutoff, neutralization, 
scaling, and dimensions of the binding pocket. The standard precision (SP) mode of Glide 
was used to explore favorable binding poses. Ligand conformation was allowed to be 
flexible, while the protein was held as a rigid structure during the docking process. After 
the first round of screening, 10,000 compounds with the highest scores were selected for 
the second round of screening using the extra precision (XP) mode of Glide, leading to the 
selection of ~2000 molecules. These molecules were filtered using AutoDock4.2 for 
binding conformation analysis [28]. The binding site on HSP47 was defined around the 
center of the collagen model peptide in the crystal structure (PDB ID: 3ZHA) [24], and was 
covered by preparing a 75 × 75 × 75 grid box with 0.375Å spacing between grid points. 
The Lamarckian genetic algorithm was applied to obtain the protein–ligand-binding free 
energies and the spatial conformations of the bound compounds.  
2.4. Turbidity Assay 
To analyze the inhibitory activity of the compounds against HSP47, a turbidity assay 
was carried out as described by Thomson [17]. Collagen from calf skin (Sigma-Aldrich, 
Gillingham, UK, Cat No: C9791) was solubilized as follows. The collagen was dissolved 
in 0.01 M acetic acid and stirred at 4 ℃ for 48 h to obtain 6 mg/mL collagen solution. On 
the day of experiment, the collagen solution was diluted by the reaction buffer (PBS: 20 
mM phosphate buffer/50 mM NaCl, pH 7.4) on ice and then added to each well of a 96-
well plate on ice. HSP47 protein together with compounds was then added to give the 
final HSP47 concentration range of 1–5 µΜ and the final collagen concentration range of 
0.2–1.2 mg/mL. Turbidity was measured at 313 nm for a period of about 90 min at 34 ℃. 
The IC50 value for each compound used to block the HSP47–collagen interaction was 
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determined by nonlinear regression using GraphPad Prism version 6.01 software (San 
Diego, CA, USA, 2012).  
2.5. Binding Affinity Measurement of HSP47 with Small Molecular Inhibitor 
The binding affinity between HSP47 and small molecular inhibitors was assessed 
using the label-free microscale thermophoresis (MST) assay. The concentration of HSP47 
was kept at 1 µM, while the concentration of the compound Hs1 varied between 0.15 and 
78 µM. The assay was performed in PBS buffer containing 0.05% Tween-20. The final 
concentration of DMSO in the assay was 5%. After a short incubation period, the samples 
were loaded into MST NT.115 label-free standard capillaries and the MST analysis was 
performed using the MST device (Monolith NT.115). Concentrations on the x-axis are 
plotted in µM.  
2.6. Molecular Docking of Small Inhibitors on HSP47 
The binding modes between HSP47 and the small-molecule inhibitors were analyzed 
using AutoDock 4.2 software. The same parameters were used as in the virtual screening. 
The results showed that Col003 and its analogs and the compounds reported by others 
preferred binding to the large subpocket1 near Asp385 on HSP47; However, for 
compound Hs1, docking showed part of the molecule binding to the small subpocket 2 
close to Arg222 on HSP47. As such, we used AutoDock Vina software [29] to confirm the 
docking results. The binding site on HSP47 was also centered on the collagen model 
peptide in the crystal structure (PDB: 3ZHA), the search spaces were set as 30Å, 30Å and 
30Å on x, y and z axes, and other parameters were set at default values. The binding 
conformations of the ligands for HSP47 were selected for further analysis by taking 
account of both the predicted binding free energy and the number of conformations 
identified. 
3. Results and Discussion 
3.1. Binding of HSP47 to the Collagen Toolkit Peptides 
To identify the HSP47 binding site on native collagens II and III, we screened HSP47 
binding sites on collagen using the collagen toolkits II and III, respectively. These kits 
contained sets of overlapping triple-helical peptides (THPs), as briefly described above 
[22]. Each peptide contains a guest sequence of 27 amino acids, the C-terminal 9 amino 
acids of which form the first 9 guest amino acids of the next peptide; thus, the toolkit 
advances 18 amino acids along the triple-helical sequence of human collagen II or III with 
each successive peptide, and a 9-amino acid overlap is included between adjacent 
peptides. These kits have been successfully used to identify many ligand-binding motifs 
on collagen [23,30,31]. Recombinant HSP47 with a C-terminal His-tag was incubated in 
wells of Immulon 2HB 96-well plates coated with toolkit peptides. Certain integrin-
binding collagen peptides (GX-4O-3GE-1R0) with an Arg at position Y0 and different 
residues at position X-4 were selected as control peptides [32–34]. 
Significant binding of HSP47 could be detected from 12 peptides, 9 derived from 
collagen II and 3 from collagen III (Table 1, Figure 1). Amongst them, four collagen II 
peptides (II-13, II-14, II-20, II-26) and one collagen III peptide (III-5) showed stronger 
binding signals. Interestingly, most of these peptides are located near the N-terminus of 
collagen. As the triple helix assembly of procollagen occurs from the C-terminus to the N-
terminus, HSP47 is likely to play a stabilization role only at the late stage of procollagen 
triple helix assembly. All of these identified HSP47-binding peptides contain the Gly-Xaa-
Arg or GXR motif, which is consistent with previous findings that the arginine residue in 
these THPs is critical for HSP47 binding; however, there are more than 40 GXR motifs in 
both collagens II and III, only 12 of which showed appreciable HSP47 binding (Figure S1, 
Figure S2). Notably, four of the five integrin-binding peptides containing GXOGER motifs 
showed strong HSP47 binding, while HSP47 binding on the fifth peptide with R at the X 
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position was relatively weak (Table 1). Together, these observations indicate that 
sequences adjacent to the GXR motif also play an important role in defining an efficient 
HSP47 binding site. This is consistent with previous observations that residues located at 
position -3 of collagen also affected the binding of HSP47 [31]. It should also be noted that 
the parent toolkit peptides that contain the same HSP47-positive, integrin-binding 
GXOGER motifs do not generally support HSP47 binding. Peptides II-7/8, II-18/19, II-28, 
and II-31 contain GLOGER, GAOGER, GFOGER, and GMOGER, respectively, but show 
negligible HSP47 binding. The same applies to peptides III-4, III-8, III-29, and III-31. This 
indicates that nearby residues (-6 and -7) may restrict HSP47 binding, as discussed further 
below. 
Table 1. Identification of HSP47-binding THPs from the toolkits II and III. GPP represents the start or finish of the [GPP]5 
host peptide, while O represents hydroxyproline (Hyp). The GXR region that is predicted to play a key role in HSP47 
binding is colored red. For the sequences that contain more than one GXR motif, we highlighted the most plausible one 
according to our energy prediction results (Figure S4c). The integrin-binding THPs with a GXOGER sequence flanked by 
[GPP]5 at both ends, where X (colored blue in the table) represents F, A, M, L, or R, were used as controls. 
Peptide Name                         Sequence                          Mean A450 
Toolkit II 
14 -------------------GPPGPRGPOGPQGATGPLGPKGQTGEOGIAGPP >2 
20 ----GPPGANGDOGROGEOGLOGARGLTGROGDAGPP >2 
13 -GPPGAKGSAGAOGIAGAOGFOGPRGPOGPQGPP 1.5-2 
26 -------------------GPPGERGEQGAOGPSGFQGLOGPOGPOGEGGPP 1.5-2 
11 ----------GPPGARGPEGAQGPRGEOGTOGSOGPAGASGPP 1-1.5 
10 -GPPGGOGFOGAOGAKGEAGPTGARGPEGAQGPP 0.5-1 
17 -GPPGKRGARGEOGGVGPIGPOGERGAOGNRGPP 0.5-1 
24 -------GPPGKAGEKGLOGAOGLRGLOGKDGETGAAGPP 0.5-1 
39 -------------------GPPGARGAQGPOGATGFOGAAGRVGPOGSNGPP 0.5-1 
Toolkit III 
5 -------------------GPPGERGLOGPOGIKGPAGIOGFOGMKGHRGPP 1.5-2 
30 ----------------GPPGAOGLRGGAGPOGPEGGKGAAGPOGPOGPP 0.5-1 
14 ----------GPPGIOGAOGLMGARGPOGPAGANGAOGLRGPP 0.5-1 
Integrin Peptide 
1 ----------------GPPGFOGERGPP >2 
2 ----------------GPPGMOGERGPP 1.5-2 
3 ----------------GPPGAOGERGPP 1.5-2 
4 ----------------GPPGLOGERGPP 1.5-2 
5 ----------------GPPGROGERGPP 0-0.5 
 
 




Figure 1. Binding of recombinant HSP47 to collagen toolkits in coated 96-well plates was measured as described in 
Material and Methods. (a) shows binding to toolkit II with collagens II and III as positive controls as indicated, and (b) to 
toolkit III, with GFOGER as positive control. BSA and GPP10 served as negative control surface coatings. Data are the 
means + S.E. of three independent experiments. 
3.2. Binding Mechanism Analysis between HSP47 and Native Collagen Peptides 
To elucidate the structural basis underlying the specific binding of these collagen 
peptides with HSP47, we analyzed their binding characteristics through structural 
modelling and binding energy calculations. A model of human HSP47 was built based on 
the reported crystal structure of canine HSP47 complexed with the triple-helical CMP 
(PPGP-7P-6GP-4T-3GP-1R0GPPGPPG, the key arginine residue is numbered as position 0). 
According to the crystal structure of the HSP47 and CMP complex, there are two copies 
of HSP47 molecules binding to a triple-helical collagen peptide in the asymmetric unit cell 
(PDB ID: 3ZHA). Each HSP47 molecule interacts mainly with one strand of the collagen 
and these two HSP47 molecules have similar binding interactions with the corresponding 
collagen strands [24]; therefore, the binding interactions between HSP47 and one strand 
of collagen were selected for subsequent analysis. The binding sites of CMP on human 
and canine HSP47 are almost identical, as human and canine HSP47 are highly similar, 
with only a few different residues. The CMP is 18 residues long, only 8 of which (P-7P-6GP-
4T-3GP-1R0) are involved in direct interactions with the β-sheet C region (yellow-colored) 
of HSP47 (Figure 2). The Arg0 in the collagen formed a salt bridge to the conserved residue 
Asp385 in HSP47 (Figure 2b), which was essential for collagen binding, as confirmed by 
mutagenic study [24]. 




Figure 2. A model of human HSP47 complexed with triple-helical collagen peptide. (a) The model was derived from the 
crystal structure of canine HSP47 complexed with collagen model peptide (CMP; PDB: 3ZHA [24]). HSP47 is shown in 
cartoon with three beta-sheets (A, B, C) colored in pale blue, green, and yellow, respectively, while its reactive center loop 
is in pink. The surface of HSP47 is shown in pale grey. The triple-helical CMP is shown in blue. (b) Close-up of the 
interaction between human HSP47 and the collagen peptide (PPGP-7P-6GP-4T-3GP-1R0GPPGPPG, cyan cartoon and lines). 
Residues of both HSP47 and CMP that are involved in interactions are shown as sticks. 
Based on this model, we then analyzed the structure–activity relationship of the 
binding between collagen peptides and HSP47 using FoldX software, which is a 
commonly-used protein stability prediction algorithm that can estimate changes in 
protein folding free energy caused by residue variations [27]. We applied FoldX to analyze 
single residue variations at different positions in CMP to estimate changes of the folding 
free energy compared to the WT complex. A lower folding free energy change (ΔΔG) 
indicates favorable binding of HSP47 and CMP. Here, we first validated this method by 
calculating the binding energies of a set of collagen model peptides with variations at 
position -3 presented in a previous report, where the bioactivities of these peptides were 
measured [31]. This showed that the calculated energy scores of these peptides are largely 
consistent with the HSP47 binding activities (Figure S3), where the most optimal residue 
at position -3 is Pro or Thr. Even though the hydroxyl group and the main chain of Thr-3 
formed polar interactions with residue Arg222 and Ser305 seen in the crystal structure of 
HSP47 (Figure 2b), Pro at this position could bind into the same pocket and has similar 
binding activities [31]. Other residues such as Hyp and Met at position -3 seemed 
compatible with HSP47 binding as well (Figure S3), while bulky or charged residue such 
as Phe, His, Arg, Trp, and Tyr were not. This is consistent with the HSP47 binding 
peptides identified here from the toolkits with Pro, Hyp, Met (III-14), or Thr (II-10) at 
position -3 (Table 1).  
Subsequently, FoldX was applied to analyze the impact of substitutions at position -
4 on the HSP47-collagen binding energy. We found that Pro and Phe at this position bind 
better than Hyp, Leu, Met, and Ala, while molecular modelling of the integrin peptide 1 
(GF-4OGER0) showed that Phe at position -4 could fit into a shallow surface cleft of HSP47, 
providing potential stabilizing interactions (Figure 3). Smaller hydrophobic residues such 
as Met and Leu seen in other integrin peptides could also be accommodated in this surface 
cleft, while the charged bulky side chain of an arginine residue could not. This readily 
explains why HSP47 binds tightly on integrin peptide 1 but very poorly on integrin 
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peptide 5 (Table 1); however, there were differences between the experimental and 
predicted results for Ala in position -4, which was likely an outlier from the calculation 
by FoldX (Table 1, Figure3). 
 
Figure 3. (a) Predicted total folding energies for the substitution of residues at position -4 in integrin peptide 1 (PPGP-7P-
6GF-4O-3GE-1R0GPPGPPG) and the HSP47 complex compared to that of WT (ΔΔG± SD, n=5, kcal/mol). The lower energy 
indicates favorable binding. (b) The predicted binding mode between triple-helical integrin peptide 1 (shown as magenta 
cartoon and sticks) and HSP47 (shown on electrostatic potential surface). 
We also assessed the effects of substitutions at positions -7 and -6 in CMP (PPGP-7P-
6GP-4T-3GP-1R0GPPGPPG), which are located at the other end of the HSP47 binding site on 
collagen. It appeared that all the non-Pro substitutions showed worse binding to HSP47 
(Figure S4). This may be due to these positions being far away from the key anchoring 
Arg0, while replacement of proline, which has a rigid sidechain, will increase the flexibility 
in this part of the triple-helical conformation, leading to lower binding activities of these 
peptides. Although not all of the unbound peptides with the GXR motif in toolkits II and 
III could be readily explained by the simple free folding energy calculation (Figure S2), 
the binding activities of collagen peptides towards HSP47 most likely reflect the overall 
cumulative effects of all of the residues involved in the HSP47–peptide binding interface. 
Arg0 is the most critical residue in collagen, but residues at positions -3 and -4 of collagen 
peptides play a critical supporting role for efficient HSP47 binding. This indicates that 
targeting the binding surfaces of HSP47 corresponding to positions -4, -3, and 0 of collagen 
simultaneously would provide a more efficient approach to blocking HSP47 activity than 
targeting the binding surface of HSP47 at position 0 only.  
3.3. Screening and Identification of HSP47 Small Molecular Inhibitors  
The binding mode between HSP47 and the collagen peptide shown above was used 
to design a virtual screening for potential HSP47 inhibitors, focusing on the footprint of 
collagen residues 0, -3, and -4 upon the surface of HSP47. After initial screening, we 
manually selected 58 compounds for subsequent inhibitory activity assay according to the 
diversity and potential interactive mechanisms between the compounds and HSP47. 
Collagen molecules in a buffer of physiological pH spontaneously associated to form 
fibrils [17,35,36], while the turbidity gradually increased in a concentration-dependent 
manner and then reached a plateau phase (Figure 4a). HSP47 retarded this fibril formation 
process within the range of 2.0–5.2 µM (Figure 4b). An HSP47 concentration of 2.6 µM 
was used for the compound activity assay (Figure 4c–e), while a previously reported 
HSP47 inhibitor, Com II, was selected as a positive control.  




Figure 4. Screening and discovery of HSP47 small molecular inhibitors. Collagen fibril formation was measured in the 
absence (a) and presence (b) of HSP47. Collagen fibril formation was monitored at 313 nm in phosphate buffer. Inhibition 
effect of Com II (c), Hs1 (d), and Hs55 (e) against HSP47 in turbidity assay. (f) The binding activity of Hs1 against HSP47 
in the label-free MST experiment. 
Our measurement showed IC50 values for Com II in the range of 50–100 µM (Figure 
4c), which was comparable to the reported value of 26.6 µM [17]. Amongst our selected 
compounds, compound Hs1 and Hs55 have the most promising activity, with IC50 values 
of 97 µM and 55 µM, respectively (Figure 4d, e). As Hs1 had better water solubility, we 
determined its binding affinity to HSP47 using microscale thermophoresis (MST). This 
revealed that Hs1 binds human HSP47 with a dissociation constant (Kd) of ~33 µM (Figure 
4f), consistent with its blocking activity in inhibiting collagen fibril formation (Figure 4d). 
3.4. Binding Modes of Small Molecular Inhibitors on HSP47 
To predict how these inhibitors would bind on HSP47, we docked these molecules 
on HSP47 using AutoDock4 and AutoDock Vina software. The docking grid box was 
defined to include the whole collagen binding region on the HSP47 surface. Apart from 
Com II, Hs1, and Hs55, a recently identified HSP47 inhibitor Col003 and its analogues 
were also selected for docking [20,36]. The docking results indicated that Com II and 
Col003 bind to the surface area of HSP47 involved in binding the GXR motif of collagen 
(colored yellow in Figure 5, subpocket1). For Com II, the nitrogen atom of the aniline 
group forms a hydrogen bond with Asp385, while the NO2 group forms a hydrogen bond 
with Gln254 and the main chain of Tyr383, which might play an essential role in the 
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compound binding. The fluorophenyl group of Com II stacks on the relatively 
hydrophobic area of HSP47 formed by Tyr245, Met271, Leu381, and Phe382. Col003 binds 
to a similar position, forming hydrogen bonds with His274 and the main chain of His273 
of HSP47 through its hydroxy group, also forming a hydrogen bond with the main chain 
of Val275 through the carbonyl group (Figures 5a and S5). Its benzyl moiety binds the 
same hydrophobic patch of HSP47 as Com II (Figure 5b and S5). In contrast, the binding 
of both Hs1 and Hs55 seems to involve both subpocket1 (Figure 5a) and the neighboring 
surface area for the docking of collagen residues at positions -3 and -4 (pale blue, 
subpocket2, Figure 5a), mimicking a collagen peptide chain binding both these surface 
pockets simultaneously. The carboxyl group of Hs1 forms hydrogen bonds with Arg222 
of HSP47, while the hydroxyl group on 9,10-dihydroanthracene forms a hydrogen bond 
with Asp385. At the same time, the 9,10-dihydroanthracene ring forms hydrophobic 
interactions with Met271, Leu381, Phe382, and Tyr383. Hs55 has a longer extended 
conformation and docks in a similarly orientation as Hs1, bridging both collagen binding 
pockets of HSP47 simultaneously. Although the binding mode of these compounds on 
HSP47 needs to be verified by structural studies, these docking results indicate that it is 
feasible to target two subpockets on the HSP47 surface at the same time. Subsequent 
chemical structure modification may improve the activities and specificity of these 
compounds for efficient HSP47 activity inhibition. 
 
Figure 5. Predicted binding mode of HSP47 inhibitors. (a) HSP47 is shown as surface presentations, while the collagen 
mode peptide (blue) is shown as a cartoon. The Arg0 binding area on HSP47 is colored yellow (subpocket 1). while the 
binding area for collagen residues at positions -4 and -3 is colored slate (subpocket 2). The potential binding interactions 
between HSP47 and the compounds Col003 (a) COM II (b), Hs1 (c), and Hs55 (d) are shown in the compounds as sticks 
and labeled. Compounds Col003, Com II, Hs1, and Hs55 are shown as magenta, cyan, green, and pink sticks, respectively. 
The black dashed lines represent the hydrogen bonds. 
4. Conclusions  
As HSP47 is an attractive therapeutic target for the treatment of fibrotic diseases. 
Understanding of its physiological binding interactions would provide valuable 
Biomolecules 2021, 11, 983 11 of 12 
 
 
information for the selection and design of small HSP47 inhibitors. Here, we identified 
the HSP47 binding sites on native collagens II and III using the collagen toolkits and 
showed that collagen binding involves two neighboring subpockets on the HSP47 surface. 
Subsequent structure-based drug screening through targeting of these surface areas 
identified two novel small-molecule HSP47 inhibitors, which might serve as lead 
compounds for the development of HSP47 inhibitors through chemical structure 
modification. 
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